Company
Headquarters: Shanghai, China
Employees: 32,258
CEO: Mr. Yifang Wu
CN¥54.32 Billion
CNY as of July 1, 2024
US$7.47 Billion
Company | Market Cap (USD) |
---|---|
Lilly | $808.65 B |
Novo Nordisk | $622.07 B |
UnitedHealth Group | $450.89 B |
Johnson & Johnson | $350.63 B |
Merck | $318.75 B |
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. researches, develops, manufactures, trades, and sells pharmaceutical products in Mainland China and internationally. It operates in five segments: Pharmaceutical Manufacturing and Research and Development, Healthcare Service, Medical Devices and Medical Diagnosis, Pharmaceutical Distribution and Retail, and Other business Operations. It offers pharmaceutical products in the areas of metabolic and digestive system; antitumor; anti-infective; central nervous system drugs; cardiovascular system; blood system; vaccines; and APIs and intermediates. The company also provides medical diagnosis and medical device products in the field of in vitro diagnostics, the products involve clinical chemistry, clinical immunity, molecular diagnostics, gene chip technology, clinical microbiology, and other fields of laboratory medicine. In addition, it offers medical services in various hospitals. The company was formerly known as Shanghai Fosun Industrial Co. Ltd. and changed its name to Shanghai Fosun Pharmaceutical (Group) Co., Ltd. in December 2004. The company was founded in 1994 and is based in Shanghai, China.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Shanghai Fosun Pharmaceutical has the following listings and related stock indices.
Stock: SSE: 600196 wb_incandescent
Stock: FSX: 08HH wb_incandescent
Stock: HKEX: 2196 wb_incandescent